Clearing of cells bearing the bcl-2 [t(14;18)] translocation from blood and marrow of patients treated with rituximab alone or in combination with CHOP chemotherapy.
Clearing of cells bearing the bcl-2 [t(14;18)] translocation from blood and marrow of patients treated with rituximab alone or in combination with CHOP chemotherapy.
复制标题
从单独使用利妥昔单抗或与 CHOP 化疗联合治疗的患者的血液和骨髓中清除带有 bcl-2 [t(14;18)] 易位的细胞。
DOI：
10.1023/a:1008395214584
复制
发表时间：
2001
期刊：
影响因子：
--
通讯作者：
D. Maloney
中科院分区：
文献类型：
--
作者：
M. Czuczman;A. Grillo‐López;P. Mclaughlin;C. White;M. Saleh;L. Gordon;A. Lobuglio;J. Rosenberg;B. Alkuzweny;D. Maloney
目的
对B细胞白血病-淋巴瘤2(BCL-2)基因重排[t(14；18)]阳性的患者进行单用利妥昔单抗或联合CHOP的疗效评估。
患者和方法
2例复发或难治性低度或滤泡性非霍奇金淋巴瘤(IWF：A-D)。单药试验每周使用375 mg/m2×4；联合治疗包括6个周期的CHOP和6个375 mg/m2的利妥昔单抗输注。用聚合酶链式反应分析基线和治疗后的骨髓(BM)和外周血(PB)标本中bcl2的表达。
结果
在单剂试验中，在基线时外周血bcl2阳性的70名患者中，36名bcl2阴性，13名保持阳性，21名在阳性和阴性之间变化。总有效率(ORR)分别为72%、31%和57%。22例重复骨髓(BM)患者中，12例在治疗3个月后bcl2阴性。在联合试验的18例患者中，8例外周血和/或骨髓中bcl2阳性。基线时PB阳性的7例患者和BM阳性的7例患者中有6例在治疗结束时均为阴性；所有患者对治疗有反应(100%ORR)。
结论
利妥昔单抗单独或与CHOP联合使用，可在超过一半的患者中根除外周血和骨髓中的bcl2阳性细胞，并与较高的总临床缓解率有关。对无病生存和总体生存的影响有待长期随访。
PURPOSE
Patients who were PCR-positive for B-cell leukemia-lymphoma 2 (bcl-2) gene rearrangement [t(14;18)] were evaluated for responses to rituximab alone or combined with CHOP.
PATIENTS AND METHODS
Patients had relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma (IWF: A-D). The single-agent trial used 375 mg/m2 weekly x 4; combination therapy included six cycles of CHOP and six 375 mg/m2 infusions of rituximab. Bcl-2 analyses of bone marrow (BM) and peripheral blood (PB) samples at base-line and following therapy were performed using a PCR assay.
RESULTS
In the single-agent trial, of 70 patients whose peripheral blood (PB) was bcl-2 positive at baseline, 36 became bcl-2-negative, 13 remained positive, and 21 varied between positive and negative. The overall response rates (ORRs) were 72%, 31%, and 57%, respectively. Twelve of twenty-two patients with repeat bone marrow (BM) samples were bcl-2-negative three months post-treatment. Of 18 patients in the combination trial, 8 were bcl-2 positive in PB and/or BM. All of seven patients positive in PB at baseline and six of seven patients positive in BM were negative at the end of therapy; all patients responded to treatment (100% ORR).
CONCLUSIONS
Rituximab, alone or combined with CHOP, eradicated bcl-2 positive cells from PB and BM in over half of the patients treated and was associated with a high overall clinical response rate. The impact on disease-free and overall survival awaits long-term follow up.
登录
查看更多内容
影响因子：
11.2
作者：
S. Krajewski;S. Tanaka;S. Takayama;M. J. Schibler;W. Fenton;John Calvin Reed
通讯作者：
S. Krajewski;S. Tanaka;S. Takayama;M. J. Schibler;W. Fenton;John Calvin Reed
影响因子：
20.3
作者：
T. Miyashita;John Calvin Reed
通讯作者：
T. Miyashita;John Calvin Reed
bcl-2 蛋白的纯化和表征。
影响因子：
3.9
作者：
Haldar,S;Jena,N;DuBois,GC;Takayama,S;Reed,JC;Fu,SS;Croce,CM
通讯作者：
Croce,CM
人滤泡性淋巴瘤中的 DNA 重排可能涉及 bcl-2 基因的 5 或 3 区域。
DOI：
10.1073/pnas.84.5.1329
发表时间：
1987
影响因子：
11.1
作者：
Tsujimoto,Y;Bashir,MM;Givol,I;Cossman,J;Jaffe,E;Croce,CM
通讯作者：
Croce,CM
通过聚合酶链反应检测 bcl-2 易位残留细胞与 B 细胞淋巴瘤自体骨髓移植后复发风险增加相关。
影响因子：
20.3
作者：
Gribben,JG;Neuberg,D;Freedman,AS;Gimmi,CD;Pesek,KW;Barber,M;Saporito,L;Woo,SD;Coral,F;Spector,N
通讯作者：
Spector,N